Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
- Not an actual patient
The DDRiver™ Clinical Trials Program
The DDRiver™ clinical trials program includes different investigational drugs that are designed to block (inhibit) a specific process in the body involved in cancer called the DNA damage response (DDR) pathway.
These investigational drugs are being studied in clinical trials to find out more about their potential efficacy against tumors and their potential side effects.
These investigational drugs have not yet been proven to be safe and effective. There is no guarantee that any of these investigational drugs will be approved for use in the future. The DDRiver™ website only highlights studies targeting key components of the DDR pathway that are sponsored by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
The DDR pathway is a complex network that has evolved to maintain genomic integrity. The DDR pathway has 4 key functions:
Visit clinicaltrials.gov to learn more about our DDR inhibitor studies conducted in collaboration with external partners.
Not an actual patient
Not an actual patient
Not an actual patient
The mechanisms in the DDRiver™ clinical trials program are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any therapies in the clinical trials program will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov.
This website is intended for patients in the US and Canada. For additional patient information, click here: https://clinicaltrials.emdgroup.com/.
© 2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. DDRiver™ is a trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.
US-MULO-00082 June 2024